U.S. Markets open in 1 hr 12 mins
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    30,504.52
    +540.31 (+1.80%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

aTyr Pharma: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of aTyr Pharma (NASDAQ:LIFE) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 69.48% over the past year to ($0.47), which beat the estimate of ($0.82).

Revenue of $2,053,000 higher by 1325.69% from the same period last year, which beat the estimate of $130,000.

Looking Ahead

aTyr Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Mar 23, 2021

View more earnings on LIFE

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/rpx2ex5c

Price Action

52-week high: $8.33

52-week low: $2.40

Price action over last quarter: Up 72.19%

Company Profile

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.